TriArm Therapeutics appoints Douglas E. Williams as CEO in San Mateo

TriArm Therapeutics, a clinical-stage cell therapy company based in San Mateo, California, has appointed Douglas E. Williams, Ph.D., as its new Chief Executive Officer. Dr. Williams brings over 30 years of experience in drug development and corporate leadership, having previously held significant roles at companies like Sana Biotechnology, Codiak BioSciences, and Biogen. His expertise includes the development of groundbreaking therapies such as Spinraza® and Tecfidera®. In his new role, Dr. Williams aims to lead TriArm through a critical growth phase, focusing on advancing safer and more effective CAR-T therapies. The company is dedicated to addressing the limitations of current CAR-T treatments, including manufacturing challenges and safety concerns. Dr. Williams expressed enthusiasm about joining TriArm at a pivotal moment, highlighting the potential of the company’s non-viral platform and unique R&D strategy. TriArm's mission is to democratize CAR-T therapy, making it more accessible and affordable for patients worldwide. The company employs a four-pronged approach that includes a rapid manufacturing process, targeted clinical programs, and a focus on marginalized patient populations. This strategy aims to overcome existing barriers in CAR-T therapy and deliver significant benefits to those in need. With Dr. Williams at the helm, TriArm is poised to make substantial progress in the field of cell therapies, leveraging his extensive background to drive innovation and regulatory approval for its differentiated products. The leadership change marks a significant step in the company’s journey toward transforming CAR-T therapy for patients globally.